Hongwei Zhi

Dr. Hongwei Zhi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
XGXiuju Guan
Xiuju Guan
HLHaitao Li
Haitao Li
LZLijuan Zhang
Lijuan Zhang
HZHongwei Zhi
Hongwei Zhi

14 October 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SZSi-Shuo Zhang
Si-Shuo Zhang
JZJi-Wei Zhang
Ji-Wei Zhang
KZKai-Xin Zhang
Kai-Xin Zhang
WCWen-Qiang Cui
Wen-Qiang Cui
HZHongwei Zhi
Hongwei Zhi
YWYa-Han Wang
Ya-Han Wang

17 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
YWYahan Wang
Yahan Wang
HLHai-Tao Li
Hai-Tao Li
KZKai-Xin Zhang
Kai-Xin Zhang
HWHong-Yun Wu
Hong-Yun Wu
WCWen-Qiang Cui
Wen-Qiang Cui
JZJi-Wei Zhang
Ji-Wei Zhang
Background Alzheimer's disease is a neurodegenerative disease that is difficult to reverse. Akt and Wnt play a role in complex cellular signaling, which is important for studying the onset of AD. This study aimed to screen key genes of the Akt and Wnt pathways as potential biomarkers for the early diagnosis and treatment of AD. Methods We searched for differentially expressed genes in the GEO database, constructed candidate gene protein-protein interaction (PPI) networks, and used least absolute shrinkage and selection operator (LASSO) regression analysis and the support vector machine-recursive feature elimination (SVM-RFE) algorithm to screen for key genes. Correlation and functional similarity analyses of key genes, immune infiltration analysis, ceRNA network construction, and drug prediction of key genes were performed. We further validated the expression of key genes in streptozotocin (STZ)-treated AD mice using quantitative reverse transcription (RT-q) PCR. Results Bioinformatic analysis identified five key genes in AD, including PRKACA, CDH3, ATP6V0C, DLL1, and CELSR2. Step-down tests, immunohistochemistry, and silver plate staining confirmed the success of STZ-induced AD in mice. RT-PCR showed that the relative expression of DLL1 mNRA in the AD group was higher than that in the control group, whereas the relative expression of ATP6V0C and PRKACA mRNA in the AD group was lower than the control group, which was consistent with the results of the bioinformatic analysis. Conclusions This study provides a basis for a more comprehensive understanding of the underlying mechanisms of AD. Furthermore, DLL1, ATP6V0C, and PRKACA may be potential intervention targets for AD.

31 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
YWYahan Wang
Yahan Wang
BLBo-Wen Li
Bo-Wen Li
CXChao Xin
Chao Xin
KZKai-Xin Zhang
Kai-Xin Zhang
HWHongyun Wu
Hongyun Wu
HZHongwei Zhi
Hongwei Zhi
Background Alzheimer's disease is a neurodegenerative disease that is difficult to reverse. Akt and Wnt play a role in complex cellular signaling, which is important for studying the onset of AD. This study aimed to screen key genes of the Akt and Wnt pathways as potential biomarkers for the early diagnosis and treatment of AD. Methods We searched for differentially expressed genes in the GEO database, constructed candidate gene protein-protein interaction (PPI) networks, and used least absolute shrinkage and selection operator (LASSO) regression analysis and the support vector machine-recursive feature elimination (SVM-RFE) algorithm to screen for key genes. Correlation and functional similarity analyses of key genes, immune infiltration analysis, ceRNA network construction, and drug prediction of key genes were performed. We further validated the expression of key genes in streptozotocin (STZ)-treated AD mice using quantitative reverse transcription (RT-q) PCR. Results Bioinformatic analysis identified five key genes in AD, including PRKACA, CDH3, ATP6V0C, DLL1, and CELSR2. Step-down tests, immunohistochemistry, and silver plate staining confirmed the success of STZ-induced AD in mice. PCR showed that the relative expression of DLL1 mNRA in the AD group was higher than that in the control group, whereas the relative expression of ATP6V0C and PRKACA mRNA in the AD group was lower than the control group, which was consistent with the results of the bioinformatic analysis. Conclusions This study provides a basis for a more comprehensive understanding of the underlying mechanisms of AD. Furthermore, DLL1, ATP6V0C, and PRKACA may be potential intervention targets for AD.